RTL Forecast, price target & analysts
RTL Target price 2025 - Analyst rating & recommendation
RTL Classifications & Recommendation:
RTL Price Target
| Target Price | €37.74 |
| Price | €35.40 |
| Potential |
6.61%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target RTL 2026 .
The average RTL target price is €37.74.
This is
6.61%
register free of charge
€43.05
21.61%
register free of charge
€29.29
17.26%
register free of charge
|
|
| A rating was issued by 11 analysts: 0 Analysts recommend RTL to buy, 5 to hold and 6 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the RTL stock has an average upside potential 2026 of
6.61%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion € | 6.25 | 6.53 |
| 0.32% | 4.46% | |
| EBITDA Margin | 14.04% | 15.93% |
| 6.08% | 13.47% |
9 Analysts have issued a sales forecast RTL 2025 . The average RTL sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an RTL EBITDA forecast 2025. The average RTL EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 2.97 | 3.80 |
| 1.33% | 27.95% | |
| P/E | 9.30 |
9 Analysts have issued a RTL forecast for earnings per share. The average RTL EPS is
This results in the following potential growth metrics and future valuations:
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
